Related Experiment Video
Updated: Jun 3, 2026

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
Detection Methods of Glycopeptide-Resistant Staphylococcus aureus I : Susceptibility Testing
Abstract:
The breakpoint for resistance to vancomycin for Staphylococcus aureus is a minimum inhibitory concentration (MIC) of greater than 8 μg/mL (1). Isolation of the first strain of MRSA resistant to vancomycin (VRSA) Mu50 was made from a Japanese surgical patient with a wound infection who had failed with vancomycin therapy (2). A strain has been described that is heterogeneously resistant to vancomycin (Mu3 strain), and it was found to be susceptible to vancomycin (MIC 2 μg/mL by NCCLS criteria), but there were cells within the Mu3 population that resisted a vancomycin concentration of up to 9 μg/mL) (1). Most of the clinical S. aureus strains having reduced susceptibility to glycopeptide antibiotics are heterogeneous in their phenotypic resistance expression. The strains contain small subpopulations of cells that have different levels of glycopeptide resistance. They are designated hetero-resistant strains, and are defined by the population analysis (see below). MIC or paper disc susceptibility tests cannot detect heteroresistant strains. It would appear that heterogeneously resistant VRSA is a preliminary stage that allows development into full resistance upon further exposure to vancomycin. Therefore, it seems reasonable to include VRSA and hetero-VRSA as possible risk factors for vancomycin therapeutic failure in MRSA infection.
Insights
Vancomycin resistance in Staphylococcus aureus can be heterogeneous, with subpopulations of cells exhibiting reduced susceptibility. These hetero-resistant strains may precede full vancomycin resistance and indicate a risk for treatment failure.
Area of Science:
- Microbiology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Vancomycin is a critical antibiotic for treating Staphylococcus aureus infections.
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant public health threat.
- Emergence of vancomycin resistance in S. aureus is a growing concern.
Purpose of the Study:
- To investigate the phenomenon of heterogeneous vancomycin resistance in Staphylococcus aureus.
- To understand the implications of hetero-resistance for vancomycin treatment efficacy.
- To identify potential risk factors for vancomycin therapeutic failure in MRSA infections.
Main Methods:
- Population analysis to define heterogeneous resistance.
- Minimum Inhibitory Concentration (MIC) testing.
- Characterization of vancomycin-resistant S. aureus (VRSA) and hetero-resistant strains (e.g., Mu3, Mu50).
Main Results:
- The breakpoint for vancomycin resistance in S. aureus is an MIC > 8 μg/mL.
- The first VRSA strain (Mu50) was isolated from a patient with treatment failure.
- Hetero-resistant strains (e.g., Mu3) possess subpopulations with high-level vancomycin resistance (up to 9 μg/mL) despite overall susceptibility.
- Standard MIC and disc susceptibility tests may not detect heteroresistance.
Conclusions:
- Heterogeneous vancomycin resistance in S. aureus may represent an intermediate step towards full resistance.
- Hetero-resistant VRSA strains are a potential risk factor for vancomycin treatment failure in MRSA infections.
- Further investigation into the mechanisms and clinical significance of hetero-resistance is warranted.
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Automated Microbial Diagnostics
Clinical Significance of Antibiotic Resistance
Methods of Classification and Identification
Differential Staining Technique
Special Staining Techniques